| (Values in U.S. Thousands) | Mar, 2026 | Mar, 2026 | Mar, 2026 | Mar, 2026 | Mar, 2026 |
| Sales | 0 | 0 | 0 | 0 | 0 |
| Sales Growth | unch | unch | unch | unch | unch |
| Net Income | 0 | 0 | 0 | 0 | 0 |
| Net Income Growth | unch | unch | unch | unch | unch |
Tanabe Pharma (MTZPY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Mitsubishi Tanabe Pharma Corp was incorporated on December 15, 1933. The Company along with its subsidiaries is engaged in the development, manufacturing, procurement, and sale of pharmaceuticals centered on ethical drugs and over-the-counter, or OTC drugs in Japan and overseas. Its products include Remicade, for the treatment of RA, Crohn's Disease, psoriasis, ulcerative colitis; Ceredist, for the treatment of spinocerebellar degeneration; Talion, for the treatment of allergic disorders; Maintate, for the treatment of hypertension, angina pectoris, extrasystole, chronic heart failure, and atrial fibrillation; Radicut, for cerebral neuroprotectant; Kremezin, Simponi, for the treatment of chronic kidney disease; Telavic, for the treatment of RA; Lexapro, for the treatment of depression; Imusera, for the treatment of multiple sclerosis;and Tenelia, for the treatment of f type 2 diabetes mellitus. In addition, the Company has vaccines, generic drugs and OTC drugs. The Company's customers include Suzuken Co. Ltd., Toho Pharmaceutical Co., Ltd., Alfresa Corporation, and Mediceo Corporation, among others.